(methylcarbamoyl)indolizin | 1126444-11-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: (methylcarbamoyl)indolizin
• 英文别名: N-methylindolizine-1-carboxamide
• CAS: 1126444-11-8
• 化学式: C₁₀H₁₀N₂O
• 分子量: 174.202
• InChiKey: TZHCUQGTWRCNOR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  33.5
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (methylcarbamoyl)indolizin 在 copper(ll) bromide 作用下， 以 乙腈 为溶剂， 反应 2.0h， 以62%的产率得到3-bromo-N-methylindolizine-1-carboxamide
  参考文献：
  名称：

  铜（II）卤化物介导的吲哚类化合物的直接官能化反应合成3-卤代吲哚并嗪

  摘要：

  3-卤代吲哚嗪是通过铜（II）卤化物介导的吲哚嗪的卤化反应合成的。这种CH直接官能化过程发生在温和的条件下，以中等至极好的收率得到3-卤代吲哚并得到的产物在Suzuki-Miyaura反应下进行了测试，从而以高收率提供了3-芳基吲哚并得到。

  DOI：

  10.1021/ol9000872

文献信息

• Desulfitative palladium-catalyzed direct C-3 arylation of indolizines with arylsulfonyl chlorides
  作者：Wei Zhang、Fang Liu、Baoli Zhao

  DOI：10.1002/aoc.3326

  日期：2015.8

  Pd‐catalyzed desulfitative approach to C‐3 arylation of indolizine derivatives has been developed, and the protocol uses readily available arylsulfonyl chlorides as the arylation reagent under nitrogen. This transformation was performed in a mixed solvent of 1‐methyl‐2‐pyrrolidone and dimethoxyethane using simple triphenylphosphine as a ligand, which provides a new method for the C‐3 arylation of indolizines

  已经开发了一种高效的Pd催化的吲哚嗪衍生物C-3芳基化脱硫方法，并且该方案使用易于获得的芳基磺酰氯作为氮气氛下的芳基化试剂。这种转化是在1-甲基-2-吡咯烷酮和二甲氧基乙烷的混合溶剂中使用简单的三苯基膦作为配体进行的，这为吲哚嗪的C-3芳基化提供了一种新方法。版权所有©2015 John Wiley＆Sons，Ltd.
• Bicyclic compounds, compositions and medicinal applications thereof
  申请人：Advinus Therapeutics Limited

  公开号：US10435402B2

  公开（公告）日：2019-10-08

  Substituted bicyclic compounds of formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, hydrates, N-oxides, co-crystals, pharmaceutically acceptable salts and pharmaceutical compositions containing them are disclosed, as well as processes for preparing and using the compounds. These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of retinoic acid-related orphan receptor gamma (RORy). Representative conditions include inflammatory and/or autoimmune disorder, rheumatoid arthritis, psoriasis, psoriatic arthritis, multiple sclerosis, inflammatory bowel disease, allergic diseases, asthma, COPD, cancer, cell proliferation, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, systemic lupus, crythematosus or other disorders.

  本发明公开了式(I)的取代双环化合物、它们的同素异形体、多晶型、立体异构体、原药、溶液剂、水合物、N-氧化物、共晶体、药学上可接受的盐和含有它们的药物组合物，以及制备和使用这些化合物的工艺。这些化合物可用于治疗、预防、预防、管理或辅助治疗与抑制视黄酸相关孤儿受体γ（RORy）有关的所有病症。具有代表性的病症包括炎症性和/或自身免疫性疾病、类风湿性关节炎、银屑病、银屑病关节炎、多发性硬化症、炎症性肠病、过敏性疾病、哮喘、慢性阻塞性肺病、癌症、细胞增殖、1 型糖尿病、重症肌无力、造血功能障碍、系统性红斑狼疮、隐性红斑狼疮或其他疾病。
• BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF
  申请人：Advinus Therapeutics Limited

  公开号：US20170362225A1

  公开（公告）日：2017-12-21

  The present disclosure relates to a class of substituted bicyclic compounds of formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, hydrates, N-oxides, co-crystals, pharmaceutically acceptable salts and pharmaceutical compositions containing them. The disclosure also relates to the process of preparation of compounds of Formula (I). These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of retinoic acid-related orphan receptor gamma (RORγ) such as inflammatory and/or autoimmune disorder, rheumatoid arthritis, psoriasis, psoriatic arthritis, multiple sclerosis, inflammatory bowel disease, allergic diseases, asthma, COPD, cancer, cell proliferation, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, systemic lupus, erythematosus or other disorders.